Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Clinical Therapeutics|January 1, 2025
Treatment Persistence Among Anti-Tumor Necrosis Factor-experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti-Tumor Necrosis Factor AgentMaryia Zhdanava, Sabree Burbage, Porpong Boonmak, et al.Current Medical Research and Opinion|May 6, 2025
The real-world effectiveness of ustekinumab in patients with ulcerative colitis in the United StatesSabree Burbage, Hannah Knight, Bridget Godwin, et al.Urology|November 3, 2024
Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in UrologyNeal Shore, Gordon Brown, Benjamin Lowentritt, et al.Advances in Therapy|August 20, 2024
Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on UstekinumabMaryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.Current Medical Research and Opinion|February 13, 2025
Real-world prevalence of potential drug-drug interactions associated with oral advanced therapies indicated for ulcerative colitisMaryia Zhdanava, Sabree Burbage, Todor I Totev, et al.Journal of Health Economics and Outcomes Research|January 2, 2026
Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone AcetateGordon Brown, Sabree Burbage, Ibrahim Khilfeh, et al.Current Medical Research and Opinion|August 6, 2024
Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumabMaryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.Advances in Therapy|August 14, 2024
Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or AdalimumabMaryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.Journal of Comparative Effectiveness Research|January 16, 2026
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamideBenjamin H Lowentritt, Sabree Burbage, Ibrahim Khilfeh, et al.Clinicoeconomics and Outcomes Research : CEOR|June 2, 2026
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United StatesNeal Shore, Benjamin Lowentritt, Charmi Patel, et al.Pageof 2